To better monitor patients on outpatient parenteral antimicrobial therapy (OPAT), we need an improved understanding of risk factors for and timing of OPAT-associated adverse drug events (ADEs).
OPAT patients in separate services at each hospital. Patients were required to have peripherally inserted central catheters, tunneled central venous catheters (CVCs), or midline catheters for OPAT. Patients were ineligible if they were in hospice care. As patients orally consented for the study and completed a telephone survey, we excluded patients who did not speak English or could not verbally consent. Eligible patients were contacted for telephone consent 2 weeks after hospital discharge, as previously described [16] . Three attempts were made to contact each patient during business hours. Patients could have used any home infusion or home nursing agency for antimicrobial agents and supplies and for training and support in CVC care, respectively.
Survey Instrument
Consenting patients underwent a 10-minute telephone survey that focused on complications such as readmissions and ADEs (Supplementary Table S1 ). The survey instrument was piloted among 10 patients prior to the study, with changes made based on feedback, focusing on OPAT outcomes [16] .
The electronic health record (EHR) was abstracted for demographic information, CVC characteristics, OPAT indication, clinical data, readmissions, and ADEs through 1 month after OPAT completion.
Variables
Age was dichotomized at 65 years, focusing on the population of patients eligible for Medicare [17] . As few enrolled patients were Asian American, Hispanic, or other racial or ethnic groups, racial or ethnic group was categorized as white non-Hispanic, black non-Hispanic, or other. Insurer was characterized as Medicare, Medicaid, or private, as few were self-pay or uninsured. The Charlson comorbidity index [18] was calculated and dichotomized at 2 based on its distribution with the outcome. OPAT days were calculated as the number of days between hospital discharge and documented OPAT completion. We counted each day of OPAT, no matter the number of antimicrobials received, as 1 day of OPAT.
The indications for OPAT were characterized by infection site. Patients could have had more than 1 indication. Only parenteral agents were recorded.
The primary outcome was a clinically significant OPATrelated ADE, that is, an ADE documented in the EHR by a physician, physician assistant, or nurse practitioner that resulted in a hospital admission, change in antimicrobial agent, early termination of antimicrobial therapy, or Clostridium difficile infection. If a patient was on more than 1 antimicrobial agent, we attributed the ADE to the agent that the clinician had determined caused the ADE. We were concerned that patients may have misattributed symptoms to their antimicrobial agents or attributed symptoms that were OPAT-related ADEs to other causes, so we included patient-reported ADEs as descriptive data only. Patients were asked whether they had experienced any side effects and to freely respond with what these side effects were including symptoms (eg, diarrhea) or laboratory abnormalities (eg, "kidney troubles"). We also reported allcause and ADE-related hospitalizations within 30 days of hospital discharge.
Data Analyses
Descriptive statistics were used for demographic, clinical, and outcome data (Stata ver. 14.0, College Station, Texas). Predictors included demographic and clinical variables. For significant ADEs, univariable and multivariable Poisson regressions were used to estimate predictors of ADEs/1000 OPAT-days. Covariates were considered if the association with the outcome was P ≤ 0.20 (2-sided) and were removed in a stepwise fashion if the covariate's association with the outcome was P > .20 (2-sided) . In addition, descriptive statistics were used to present patient-reported ADEs. Kappa scores were reported between patient-reported ADEs and ADEs identified through the EHR. A total of 322 patients were needed to achieve 80% power to calculate a 50% difference in the primary relationship.
The study was approved as expedited with oral consent by the Johns Hopkins University School of Medicine Institutional Review Board.
RESULTS
Of 672 patients discharged on OPAT, 570 were eligible for the study and 339 enrolled in the study (59.5%, 21 878 home OPATdays; Supplementary Figure S1 ). Osteomyelitis was the most common indication for OPAT (N = 102, 30.1%). The most common antimicrobial agents prescribed were vancomycin (N = 89, 26.3%), ceftriaxone (N = 41, 12.1%), and piperacillin-tazobactam (N = 39, 11.5%). Patients were on OPAT for a median of 29 days (Table 1) .
ADEs were common (Table 2) ; 61 patients had a clinician-documented ADE (18.0%). Of these, 49 were considered clinically significant and were included in the primary outcome (14.5%, 2.24/1000 OPAT-days).
We assessed clinician-documented ADEs, including all ADEs and clinically significant ADEs (Table 3) . Only 1.5% of patients in this study developed C. difficile infections. Vancomycin led to ADEs in 18.0% of patients (N = 61), of which 19 (21.3%) were clinically significant, most commonly nephrotoxicity (N = 11, 18.0%). Ceftriaxone led to only 1 ADE (2.5%), which was not clinically significant (nausea, which was not treated). Piperacillin-tazobactam led to ADEs in 5 patients (16.7%), of which 4 (10.3%) were clinically significant (C. difficile infection, N = 1; nephrotoxicity, N = 1; hepatotoxicity, N = 1; edema necessitating hospitalization, N = 1). Only 6 patients had ADEs that led to early termination within 0-13 days (8.0% of N = 75 patients on 0-13 OPAT-days). Adjusted incidence risk ratios (aIRRs) were calculated for significant ADEs/1000 OPAT-days (Table 4) . Independent predictors of having a significant ADE included female gender (aIRR, 2.56; 95% confidence interval [CI], 1.40-4.67), receipt of daptomycin (aIRR, 11.77; 95% CI, 2.67-51.84), and receipt of vancomycin (aIRR, 2.19; 95% CI, 1.78-5.72). Independent predictors of not having a significant ADE included uncomplicated bacteremia (aIRR, 0.30; 95% CI, 0.13-0.68) and being empirically treated with antimicrobial therapy (aIRR, 0.35; 95% CI, 0.16-0.76). The longer patients were on OPAT, the less likely they were to have a significant ADE (vs being on OPAT for 0-13 days; 14-27 days: aIRR, 0.35; 95% CI, 0.14-0.87 and ≥28 days: aIRR, 0.15; 95% CI, 0.070-0.32).
Patient-reported ADEs were more frequent than clinician-reported ADEs (Table 5 ). A total of 97 patients (28.6%) reported any ADE, only 39 of which were also clinician reported. Meanwhile, clinicians reported 22 ADEs that were unreported by patients. Interrater reliability between patient-reported and clinician-reported total ADEs was only κ = 0.35. Many ADEs reported by both patients and clinicians were laboratory abnormalities (N = 10). Notably, patients frequently reported ADEs such as loss of appetite, fatigue, malaise, and mucocutaneous candidiasis that clinicians did not report. Of the most commonly prescribed OPAT agents, 43.8% of patients on vancomycin reported an ADE (N = 39), 26.8% of patients on ceftriaxone reported an ADE (N = 11), and 33.3% of patients on piperacillin-tazobactam reported an ADE (N = 13).
Basic demographic, CVC information, and 30-day all-cause readmissions were abstracted for the 231 patients who were eligible for the study but either declined participation or were unable to be reached. No differences were detected.
DISCUSSION
In this prospective cohort of OPAT patients, 14.5% (2.24/1000 OPAT-days) had a significant ADE that required a change in therapy, early termination of therapy, readmission, or resulted in C. difficile infection. Total ADEs were even more common, occurring in 18.0% of patients. In their first 2 weeks of OPAT, patients were at a higher risk of developing a significant ADE. These findings underscore the importance of judiciously prescribing OPAT agents, ensuring appropriate dosage of medication, educating patients about ADEs, and carefully monitoring for ADEs.
Previous studies on ADEs in OPAT have largely been retrospective chart reviews [2, 6, [19] [20] [21] [22] [23] [24] [25] [26] [27] . Incidences of ADEs in prior studies have varied, possibly depending on ADE definition or the population or condition examined [2, 6, 28, 29] . In this study, we enrolled consenting patients discharged on home-based OPAT and defined ADEs as those that were clinically significant (causing a change in antimicrobial agent, early termination of therapy, readmission, or C. difficile infection). We also reported patient-reported ADEs, although as descriptive data only as we were concerned about misattribution of symptoms. Our data suggest that ADEs may be highest in the first 2 weeks of OPAT. The hospital-to-home transition is a time when medication errors are common [30, 31] and, in the absence of close monitoring, frequently occur among OPAT patients [2] . Dosing or other medication changes may occur just prior to hospital discharge, and patients who initiate therapy immediately after discharge may make errors as they learn to perform OPAT-related tasks [32] . Evidence-based education that starts at the hospital bedside is needed to mitigate this highrisk period. The transition home in OPAT is a time when clinical monitoring and timely laboratory testing is particularly important.
ADE incidence was lower than in several recent studies, such as one where 44.4% of patients experienced an ADE, although only 26% resulted in therapeutic changes [13] . Our rate of significant ADEs was also lower than a prior study's rate of 4.5/1000 days [12] , perhaps as our study focused on the most clinically significant ADEs. Our incidence of ADEs was slightly lower than in inpatients, where 20% of patients receiving an antibiotic for 24 hours or longer had an ADE [33] . In an inpatient population, many medications are initiated simultaneously in patients who may have been already critically ill, while patients in our study had already initiated therapy prior to study entry. We also assessed which antimicrobial agents led to ADEs. Among antimicrobial agents received by at least 15 patients, those who received cefazolin, ceftriaxone, penicillin, and piperacillin-tazobactam had few clinically significant ADEs (6.7%, 0.0%, 5.6%, and 6.1%, respectively), while patients who received vancomycin, ampicillin-sulbactam, and ertapenem had frequent clinically significant ADEs (21.3%, 19.1%, and 15.4%, respectively). Vancomycin in particular frequently led to nephrotoxicity and cytopenias, as in prior studies [14, 34] . Although a prior study of OPAT patients suggested that patients discharged on vancomycin had more ADEs than patients discharged on daptomycin [14] , we found an association between daptomycin and ADEs as well. In our patient population, patients were typically discharged on daptomycin only for complicated vancomycin-resistant Enterococcus infections or for methicillin-resistant Staphylococcus aureus infections that did not respond to vancomycin; patients who had had a prior ADE to vancomycin were also typically discharged. These patients may be sicker than other patients or require higher doses of daptomycin. Our data suggest that patients on vancomycin and daptomycin be monitored closely.
We identified risk factors for ADEs. As in at least 1 other study, we did not find an association between older age and ADEs [19] . However, women had a higher rate of ADEs. This Abbreviations: ADE, adverse drug event; aIRR: adjusted incidence rate ratio; CI, confidence interval; IRR, incidence rate ratio; OPAT, outpatient parenteral antimicrobial therapy.
Significant ADEs resulted in change in antimicrobial agent, stopping antimicrobial therapy early, readmission due to ADE, or Clostridium difficile infection. ADEs were recorded in the medical record by a clinician (physician, nurse practitioner, or physician assistant).
may be related to a lower volume of distribution in women. Dosing of antimicrobials and monitoring for ADEs may be particularly important in women. Uncomplicated bacteremia was associated with a lower ADE rate, as was empiric therapy. It is possible that patients with uncomplicated bacteremia were less ill than those with complicated bacteremia or infections in other locations, making these patients less susceptible to ADEs. In addition, it is possible that culture-negative infections were due to a lower burden of pathogens or less-virulent pathogens, and therefore patients who were empirically treated may also be less ill.
Although we focused on clinician-documented clinically significant ADEs, patient-and clinician-reported ADEs often did not correlate. Most patient-reported ADEs were symptoms (eg, poor appetite, nausea and vomiting, dizziness, diarrhea). It is possible that patients did not think many of these ADEs were significant enough to mention to a clinician or clinicians did not think them important enough to document. As OPAT occurs in the home without direct observation by clinicians, it is likely that ADEs are underreported. However, many clinically significant laboratory-based ADEs were reported by both clinicians and patients, perhaps indicating that clinicians had explained to patients why a change in antimicrobial agent was needed. OPAT may cause even more ADEs than previously recognized. Patients should be informed about the possibility of ADEs and asked to report these. We believe that our study enhances the OPAT literature in several ways. We used a prospective cohort. Our primary analysis focused on clinician-defined, clinically significant ADEs as we felt that clinicians would be most interested in ADEs that result in a change in antimicrobial agent, early termination of therapy, readmission, or C. difficile infection. We also measured patient-reported ADEs to understand the patient experience.
Our study did have several limitations. First, our population may not represent other OPAT populations as this study was performed at 2 urban, academically affiliated hospitals where medically complex populations were cared for (12.1% had a solid organ transplant, 26.8% were undergoing treatment for a malignancy, and 7.7% had cystic fibrosis). We excluded non-English speakers because patients were required to orally consent and respond to a telephone survey. Some antimicrobials (eg, aminoglycosides, tigecycline, ceftaroline, liposomal amphotericin) were prescribed too infrequently to include in our analyses. Patients initiated their antimicrobial agents prior to hospital discharge; we did not include predischarge data as we were concerned that antimicrobial agents may frequently be changed in the hospital, making ADE attribution difficult. We likely underestimated ADEs as we required clinician documentation; patients may not inform clinicians of all symptoms, clinicians may not document all ADEs, and not all laboratory test results may be received by clinicians. There may have also been variation in clinician-reported ADEs; one clinician may have made a change in antimicrobial agent due to a symptom while another may have elected to monitor the patient closely. In addition, we were unable to evaluate data from patients who had medical care outside of the 9 hospitals and affiliated clinics linked to our EHR. We did not collect data on oral antimicrobial agents or on other medications, so some of the ADEs experienced may have been misattributed to OPAT. Some OPAT courses may have been terminated early due to ADEs. However, only 6 of 19 patients who experienced an ADE that led to early termination of therapy experienced this ADE within the first 2 weeks of hospital discharge.
Our data suggest that ADEs are common and often can be detected by laboratory testing or clinical assessment. Guidelines based on expert opinion suggest that OPAT patients receive weekly clinic visits and regular laboratory monitoring [15, 35] . This recommendation may be based on an assumption that laboratory testing will be received and reviewed by the ordering provider on a timely basis. However, most infectious diseases clinicians do not have a way to ensure receipt of ordered laboratory test results [2, 36] . In the absence of a care coordination program that allows for rapid communication between patients, inpatient clinicians, outpatient clinicians, home health agencies, and home infusion agencies, as few as 30% of laboratory tests may be received by the provider [2] . Physician nonreceipt of OPAT-related laboratory testing is associated with increased admissions [37] . Care coordination can improve compliance with laboratory testing [2, 3] and may prevent ADEs.
Our study indicates that close monitoring of OPAT patients for ADEs may be particularly essential in the first 2 weeks after hospital discharge. Patients on daptomycin or vancomycin as well as women may need closer monitoring for ADE development. To prevent harm from ADEs, patients should be monitored closely, especially in the first 2 weeks after discharge, with laboratory testing and clinic visits.
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